Brief: ALX Oncology Reports Encouraging Clinical Data Of Evorpacept In Combination With Standard-Of-Care In An Ongoing Phase 1/2 Clinical Trial In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

ALX Oncology Holdings

09/04/2024 22:46

April 9 (Reuters) - ALX Oncology Holdings Inc  ALXO.O :
    * ALX ONCOLOGY REPORTS ENCOURAGING CLINICAL DATA OF
EVORPACEPT IN
COMBINATION WITH STANDARD-OF-CARE IN AN ONGOING PHASE 1/2
CLINICAL TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL
NON-HODGKIN LYMPHOMA (“R/R B-NHL”)
    * ALX ONCOLOGY HOLDINGS INC - EVORPACEPT PLUS R(2) WAS WELL
TOLERATED WITH A SAFETY PROFILE SIMILAR TO HISTORICAL R(2)

Source text for Eikon:  ID:nGNXc3k1Bj 
Further company coverage:  ALXO.O 

 ((Reuters.Briefs@thomsonreuters.com;))